XML 28 R11.htm IDEA: XBRL DOCUMENT
v3.22.0.1

Inventory | 12 Months Ended
--- | ---
Dec. 31, 2021
Inventory Disclosure [Abstract] |
Inventory, Net | Inventory, Net All of the Company's inventory relates to the manufacturing of MARGENZA. The following table sets forth the Company's inventory, net of reserves (in thousands):
| December 31, 2021 |  |
Work in process | $ | 3,929 |  |  |
Finished goods | 459 |  |  |
Total inventory, net | $ | 4,388 |  |  |
Prior to FDA approval of MARGENZA in December 2020, the cost of materials and expenses associated with the manufacturing of MARGENZA were recorded as research and development expense. Subsequent to FDA approval, the Company began capitalizing inventory costs related to the manufacture of MARGENZA. The inventory balance as of December 31, 2021 is net of a reserve of $2.0 million for unsaleable inventory which is reflected in cost of product sales for the year ended December 31, 2021.
| Inventory Reserves (in thousands)
| Balance at Beginning of Year |  | Additions Charged to Expenses |  | Deductions |  | Balance at End of Year
Year Ended December 31, 2021 | $ | — |  |  | $ | (2,035) |  |  | $ | — |  |  | $ | (2,035) |

X
- References No definition available. + Details
Name: | us-gaap_InventoryDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 330 -URI http://asc.fasb.org/topic&trid=2126998 + Details
Name: | us-gaap_InventoryDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration